Costs of HIV prevention among out-of-treatment drug-using women: Results of a randomized controlled trial

Public Health Reports

Volumn 125, Issue SUPPL. 1, 2010, Pages 83-94

  Ruger, Jennifer Prah ^a   Abdallah, Arbi Ben ^b   Cottler, Linda ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG USE; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH HAZARD; HIV EDUCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; ADDICTION; CONDOM; COST; ECONOMICS; PATIENT EDUCATION; VAGINA SMEAR;

CONDOMS; CONDOMS, FEMALE; COSTS AND COST ANALYSIS; FEMALE; HIV INFECTIONS; HUMANS; PATIENT EDUCATION AS TOPIC; SEXUALLY TRANSMITTED DISEASES; SUBSTANCE-RELATED DISORDERS; VAGINAL SMEARS;

EID: 77952522088     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/00333549101250s111     Document Type: Article

References (26)

1. Holtgrave DR, Curran JW. What works, and what remains to be done, in HIV prevention in the United States. Annu Rev Public Health 2006;27:261-75.
2. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Costeffectiveness in health and medicine. New York: Oxford University Press; 1996.
3. Johnson-Masotti AP, Pinkerton SD, Kelly JA, Stevenson LY. Costeffectiveness of an HIV risk reduction intervention for adults with severe mental illness. AIDS Care 2000;12:321-32.
4. Pinkerton SD, Holtgrave DR, DiFranceisco WJ, Stevenson LY, Kelly JA. Cost-effectiveness of a community-level HIV risk reduction intervention. Am J Public Health 1998;88:1239-42.
5. Pinkerton SD, Holtgrave DR, Jemmott JD 3rd. Economic evaluation of HIV risk reduction intervention in African-American male adolescents. J Acquir Immune Defic Syndr 2000;25:164-72.
6. Trentacoste ND, Holtgrave DR, Collins C, Abdul-Quader A. Disseminating effective behavioral interventions for HIV prevention: a cost analysis of a risk-reduction intervention for drug users. J Public Health Manag Pract 2004;10:130-9.
7. Zarkin GA, Lindrooth RC, Demiralp B, Wechsberg W. The cost and cost-effectiveness of an enhanced intervention for people with substance abuse problems at risk for HIV. Health Serv Res 2001;36:335-55.
8. Cottler LB, Compton WM, Ben Abdallah A, Cunningham-Williams R, Abram F, Fichtenbaum C, et al. Peer-delivered interventions reduce HIV risk behaviors among out-of-treatment drug abusers. Public Health Rep 1998;113(Suppl 1):31-41.
9. Cunningham RM, Cottler LB, Compton WM. Are we reaching and enrolling at-risk drug users for prevention studies? J Drug Issues 1996;26:541-60.
10. Wechsberg WM, MacDonald BR, Dennis ML, Inciardi JA, Surratt HL, Leukefeld CG, et al. The standard intervention for reduction in HIV risk behavior: protocol changes suggested by the continuing HIV/AIDS epidemic. Bloomington (IL): Chestnut Health Systems/ Lighthouse Institute; 1997.
11. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press; 1997.
12. Gorsky RD. A method to measure the costs of counseling for HIV prevention. Public Health Rep 1996;111(Suppl 1):115-22.
13. Holtgrave DR, editor. Handbook of economic evaluation of HIV prevention programs. New York: Plenum Press; 1998.
14. Department of Labor (US), Bureau of Labor Statistics. Labor force statistics from the current population survey: characteristics of minimum wage workers: 2005 [cited 2009 Sep 17]. Available from: URL: http://www.bls.gov/cps/ minwage2005tbls.htm
15. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997;16:1-31.
16. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 1990; 6:57-75.
17. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:54-62.
18. Department of Labor (US), Bureau of Labor Statistics. Consumer price index - medical care (seasonally adjusted, U.S. city average) [cited 2009 Sep 17]. Available from: URL: http://data.bls.gov/labjava/outside.jsp?survey=cu
19. Holtgrave DR. Using economic threshold analysis to determine the intensity of HIV prevention services for HIV-seropositive persons. AIDS 2005;19:2025-9.
20. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006;44:990-7.
21. Ekwueme DU, Pinkerton SD, Holtgrave DR, Branson BM. Cost comparison of three HIV counseling and testing technologies. Am J Prev Med 2003;25:112-21.
22. World Health Organization. The importance of simple/rapid assays in HIV testing. Wkly Epidemiol Rec 1998;73:321-8. Also available from: URL: http://www.who.int/wer/pdf/1998/wer7342.pdf [cited 2005 Nov 31].
23. Holtgrave DR, Pinkerton SD, Merson M. Estimating the cost of unmet HIV-prevention needs in the United States. Am J Prev Med 2002;23:7-12.
24. Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS 2001;15:917-28.
25. Manning WG Jr. Panel on cost-effectiveness in health and medicine recommendations: identifying costs. J Clin Psychiatry 1999;60(Suppl 3):54-6.
26. Ruger JP. Combating HIV/AIDS in developing countries. BMJ 2004; 329:121-2.